ReviewThe Journal of antimicrobial chemotherapy2004
A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.
Review in The Journal of antimicrobial chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- SARS-CoV: Lessons learned; opportunities missed for SARS-CoV-2.Reviews in medical virology · 2021Review
- Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.Journal of virology · 2016Article
- Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study.PloS one · 2012Article
- High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design.Computational biology and chemistry · 2010Article
- Prediction of mutations engineered by randomness in H5N1 neuraminidases from influenza A virus.Amino acids · 2008Article
- Antiviral agents active against influenza A viruses.Nature reviews. Drug discovery · 2006Review
- Recent highlights in the development of new antiviral drugs.Current opinion in microbiology · 2005Review
- Generation of predictive pharmacophore model for SARS-coronavirus main proteinase.European journal of medicinal chemistry · 2005Article
- Article
- Prediction of mutations in H1 neuraminidases from North America influenza A virus engineered by internal randomness.Molecular diversityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A and B viruses cause serious medical problems and social disruption every year in particular countries of the world. The virus is notoriously fickle and may attack citizens in say two adjacent countries but not the third. More rarely a global pandemic virus emerges causing millions of deaths worldwide. The SARS outbreak has illuminated weaknesses in planning for sudden outbreaks of disease in a modern society and in particular how panic can grip and cause intense economic disruption. Many communities in the world are neither prepared for a global pandemic nor a very acute epidemic of influenza. The neuraminidase inhibitors (NAIs) are a new class of antiviral drug targeting a viral influenza enzyme, the neuraminidase, which acts both to facilitate virus infection of cells by clearing a passage through otherwise protective respiratory fluids and also by helping release of the virus by cutting the chemical umbilical cord which links up the virus to the infected cell. Extensive laboratory studies of the two molecules zanamivir and oseltamivir have shown that they block all influenza A and B viruses yet tested and would, in theory, even inhibit the 1918 pandemic virus. Both drugs can be used prophylactically to prevent spread of infection in families and communities where 80-90% protection has been documented. The therapeutic effects are also strong in adults and children abbreviating infection, reducing quantities of excreted virus and reducing antibiotic prescriptions. The drugs have to be taken within 48 h of the onset of symptoms. Drug resistance is not a problem at present because although such mutants occur the mutants are compromised and are less virulent than their drug-sensitive parents and they spread less easily. The two drugs could be stockpiled to prepare for an influenza pandemic but, importantly, clinical and scientific experience need to be gained by using these inhibitors in the yearly conflagrations of epidemic influenza, which unchecked do great harm to our communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.